Tonix Pharmaceuticals Holding Corp.
tonixpharma.comWhat Do They Do?
Sells Zembrace SymTouch injections and other prescription medicines for acute migraine and fibromyalgia to pharmaceutical wholesalers, pharmacies and specialty distributors.
10-K for FY2025, filed Mar 12, 2026Zembrace SymTouch (sumatriptan injection) 3 mg is a low-dose autoinjector designed for ease of use and rapid onset of action. Zembrace is…View ↗
Zembrace SymTouch and Tosymra are both indicated for the treatment of acute migraine with or without aura in adults. Zembrace SymTouch is…View ↗
Marketing activity for TONMYA, Zembrace Symtouch and Tosymra in the United States is conducted by our wholly-owned subsidiary, Tonix…View ↗
How Do They Make Money?
Customers buy Tonix's prescription medicines, with product sales generally occurring when products ship or are delivered; payment terms are typically 30 to 90 days.
10-K for FY2025, filed Mar 12, 2026The Company records and recognizes revenue in a manner that depicts the transfer of promised goods or services to customers in an amount…View ↗
-
10-K for FY2025, filed Mar 12, 2026
FY2025 revenue by product or service ↗
$13.1M
-
10-K for FY2025, filed Mar 12, 2026
$13.1M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Tonmya
Sold outright
10-K for FY2025, filed Mar 12, 2026 |
11% |
Tonmya, FY2025
$1.4M Sources
|
Sold outright |
|
Zembrace Symtouch
Sold outright
10-K for FY2025, filed Mar 12, 2026 |
71% |
Zembrace Symtouch, FY2025
$9.3M Sources
|
Sold outright |
|
Tosymra
Sold outright
10-K for FY2025, filed Mar 12, 2026 |
18% |
Tosymra, FY2025
$2.4M Sources
|
Sold outright |
Who Are Their Customers?
The medicines are sold mainly to pharmaceutical wholesalers, pharmacies and specialty distributors; sales and marketing target physicians in private practice and public treatment systems.
10-K for FY2025, filed Mar 12, 2026Marketing activity for TONMYA, Zembrace Symtouch and Tosymra in the United States is conducted by our wholly-owned subsidiary, Tonix…View ↗
10-K for FY2025, filed Mar 12, 2026
For the year ended December 31, 2025, revenues from five customers accounted for 24%, 22%, 21%, 19% and 12% of net product revenues…View ↗
Do Revenues Turn Into Profits?
No. It lost $124M in FY2025.
10-K for FY2025, filed Mar 12, 2026
−$125.7MView ↗
10-K for FY2025, filed Mar 12, 2026
−$124MView ↗
10-K for FY2025, filed Mar 12, 2026
−$103.2MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 10, 2026
−$40.6MView ↗
- ▲ +43% (Loss)
- vs −$28.3M in Q2 FY2025
10-Q for Q2 FY2026, filed Aug 10, 2026
Open tableView ↗
From development to sales
The business has moved from clinical-stage drug development to selling approved medicines for fibromyalgia and acute migraine, while continuing development programs.
10-K for FY2022, filed Mar 13, 2023 10-K for FY2025, filed Mar 12, 2026We are a clinical-stage biopharmaceutical company focused on developing therapeutics and vaccines to treat and prevent human disease and…View ↗
Who Do They Compete With?
Competes with Axsome Therapeutics, Dogwood Therapeutics, Ono Pharmaceutical, Tryptamine Therapeutics, Pfizer, AbbVie, Satsuma Pharmaceuticals, Pulmatrix, Johnson & Johnson, Luye Pharma Group, Definium Therapeutics, Vanda Pharmaceuticals, BioXcel Therapeutics, Valneva, Moderna, Sanofi, Eledon Pharmaceuticals, Amgen, UCB, and Biogen
10-K for FY2025, filed Mar 12, 2026We actively monitor multiple companies advancing investigational therapies for fibromyalgia. In the U.S., Axsome Therapeutics, Inc.…View ↗
Loading...
